ReviewFuture oncology (London, England)2025
Selpercatinib in the treatment of thyroid cancer.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Signaling pathways and targeted therapy in high‑risk refractory thyroid cancer: From bench to bedside (Review).International journal of oncology · 2026Review
- Inhibition of TGF-β1/Smad signaling reverses the dedifferentiated phenotype of thyroid cancer cells in three-dimensional culture.Journal of endocrinological investigation · 2026Article
- Real-world clinical responses to selpercatinib in RET M918T-mutant medullary thyroid carcinoma.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selpercatinib, a highly selective RET inhibitor, represents a major advancement for RET-driven thyroid cancers, including medullary thyroid cancer (MTC) and radioiodine-refractory differentiated thyroid cancer (DTC). Clinical trials, such as LIBRETTO-001 and LIBRETTO-531, demonstrate its superior efficacy, safety, and tolerability compared to the less specific multikinase inhibitors, with overall response rates exceeding 84% in treatment-naïve RET-mutant MTC and 95% in RET fusion-positive DTC. Real-world studies further confirm its long-term benefits in diverse populations. With approvals from the U.S. FDA and EMA, selpercatinib is recommended as a first-line therapy for advanced RET-mutant MTC and as a second-line option for RAIR DTC. This review explores the molecular underpinnings of thyroid cancer, highlights the therapeutic landscape, and delves into the clinical performance of selpercatinib.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.